Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 13, 2024 06:00 ET | Source: Fractyl Health, Inc.

Fractyl Health Presents Clinical Update on Revita® German Real-World Registry for Patients With Advanced Type 2 Diabetes (T2D)

FRACTYL HEALTH PRESENTS CLINICAL UPDATE ON REVITA® GERMAN REAL- WORLD REGISTRY FOR PATIENTS WITH ADVANCED TYPE 2 DIABETES (T2D)
May 08, 2024 06:00 ET | Source: Fractyl Health, Inc.

Fractyl Health to Present at BofA Securities 2024 Health Care Conference

Fractyl Health to Present at BofA Securities 2024 Health Care Conference
May 07, 2024 06:00 ET | Source: Fractyl Health, Inc.

Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024

Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024
April 30, 2024 08:38 ET | Source: Fractyl Health, Inc.

Fractyl Health Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference and the German Diabetes Association (DDG) Annual Meeting

Fractyl Health Announces Multiple Presentations at DDW 2024 Conference and the German Diabetes Association (DDG) Annual Meeting
April 02, 2024 08:00 ET | Source: Fractyl Health, Inc.

Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes

Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation
April 01, 2024 07:00 ET | Source: Fractyl Health, Inc.

Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
April 01, 2024 06:00 ET | Source: Fractyl Health, Inc.

Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs

Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs
March 12, 2024 14:06 ET | Source: Fractyl Health, Inc.

UPDATE -- Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity

Fractyl Health today announced promising new preclinical findings for the first clinical candidate in its Rejuva® pancreatic gene therapy platform.
March 12, 2024 08:38 ET | Source: Fractyl Health, Inc.

Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity

Fractyl Health today announced promising new preclinical findings for the first clinical candidate in its Rejuva® pancreatic gene therapy platform.
February 20, 2024 08:38 ET | Source: Fractyl Health, Inc.

Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical Trials

Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical Trials

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right